Skip to main content
Premium Trial:

Request an Annual Quote

Incyte, Epoch Biosciences Enter Licensing and Development Deal

SAN FRANCISCO, Oct. 10 – Incyte Genomics has enter a licensing and development alliance with molecular tools manufacturer Epoch Biosciences, the companies announced Wednesday.

The terms include Epoch’s licensing Palo Alto-based Incyte’s LifeSeq Gold and ZooSeq databases for development of oligonucleotide probes and Incyte naming Epoch the “preferred provider” of custom oligonucleotide probes in addition to receiving Epoch Eclipse Probe Systems for use in internal development.

Financial details of the agreement were not disclosed.

“Epoch is recognized for its leading technologies related to the development of enhanced genetic analysis tools,” Roy A. Whitfield, CEO of Incyte, said in a statement. “This alliance with Epoch leverages their probe design and manufacturing capabilities and provides our users of LifeSeq Gold with a source of reliable probes to enhance their genetic analysis and research efforts.”

Epoch Biosciences is based in Bothell, Wash.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more